Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.
Authors
Ulrich Keilholz
Charité Comprehensive Cancer Center, Berlin, Germany
Ulrich Keilholz, Andrzej Kawecki, Andreas Dietz, Bogdan Zurawski, Michael Schenker, Bozena Kukielka-Budny, Philippe Schafhausen, Anca C. Mihailov, Sebastian Ochenduszko, Ilaria Imarisio, Simona Mihutiu, Cristina-Marinela Oprean, Gunnar Folprecht, Alina Turcu, Sylvie Rottey, Philippe Debourdeau, Javier Lavernia, Bruno Dietrich, Alfredo Zurlo, Jerome Fayette
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02052960
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 59)
DOI
10.1200/JCO.2018.36.5_suppl.59
Abstract #
59
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
First Author: Kevin Joseph Harrington
Poster
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
First Author: A. Dimitrios Dimitrios Colevas
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2020 ASCO Virtual Scientific Program
Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman